| Philip Matthew Oconnell, MD | |
|
2060 Dan Proctor Drive Suite 2100, Southeast Georgia Health System, St. Marys, GA 31558 | |
| (912) 882-6767 | |
| (912) 882-6411 |
| Full Name | Philip Matthew Oconnell |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 31 Years |
| Location | 2060 Dan Proctor Drive Suite 2100, St. Marys, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518930841 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 69080 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kindred At Home | Savannah, GA | Home health agency |
| Advantage Home Health | Brunswick, GA | Home health agency |
| Southeast Georgia Health System -- Camden Campus | Saint marys, GA | Hospital |
| Baptist Health Medical Center - Jacksonville | Jacksonville, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cooperative Healthcare Services, Inc. | 9830093640 | 171 |
News Archive
In what some leading cardiologists are calling a "blockbuster" study, new research could alter the approach to treating patients who have cardiovascular disease but may not be at immediate risk of heart attack or stroke.
With a House vote scheduled for Thursday, the White House is on record opposing the "offset" used to pay for the repeal of this reporting provision included in the health law, but it also stopped short of threatening a veto. This part of the bill also may cause it to lose bipartisan support in the lower chamber.
Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies.
Virginia Commonwealth University researchers studying a key molecular player called Hsp70 that is responsible for protein homeostasis have uncovered how it binds together with another molecule responsible for intracellular energy transfer to enhance its overall activity and efficiency - details that have previously not been well understood.
› Verified 9 days ago
| Entity Name | Cooperative Healthcare Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417979402 PECOS PAC ID: 9830093640 Enrollment ID: O20031124000222 |
News Archive
In what some leading cardiologists are calling a "blockbuster" study, new research could alter the approach to treating patients who have cardiovascular disease but may not be at immediate risk of heart attack or stroke.
With a House vote scheduled for Thursday, the White House is on record opposing the "offset" used to pay for the repeal of this reporting provision included in the health law, but it also stopped short of threatening a veto. This part of the bill also may cause it to lose bipartisan support in the lower chamber.
Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies.
Virginia Commonwealth University researchers studying a key molecular player called Hsp70 that is responsible for protein homeostasis have uncovered how it binds together with another molecule responsible for intracellular energy transfer to enhance its overall activity and efficiency - details that have previously not been well understood.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Philip Matthew Oconnell, MD 2060 Dan Proctor Drive Suite 2100, Southeast Georgia Health System, St. Marys, GA 31558 Ph: (912) 882-6767 | Philip Matthew Oconnell, MD 2060 Dan Proctor Drive Suite 2100, Southeast Georgia Health System, St. Marys, GA 31558 Ph: (912) 882-6767 |
News Archive
In what some leading cardiologists are calling a "blockbuster" study, new research could alter the approach to treating patients who have cardiovascular disease but may not be at immediate risk of heart attack or stroke.
With a House vote scheduled for Thursday, the White House is on record opposing the "offset" used to pay for the repeal of this reporting provision included in the health law, but it also stopped short of threatening a veto. This part of the bill also may cause it to lose bipartisan support in the lower chamber.
Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies.
Virginia Commonwealth University researchers studying a key molecular player called Hsp70 that is responsible for protein homeostasis have uncovered how it binds together with another molecule responsible for intracellular energy transfer to enhance its overall activity and efficiency - details that have previously not been well understood.
› Verified 9 days ago
Dr. Scott Thomas Miles, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5155 Ga Highway 40 East, St. Marys, GA 31558 Phone: 912-434-1794 Fax: 912-662-8785 |